EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EYPT Investors With Losses to Contact the Firm

EyePoint reported topline results from its first pivotal Phase 3 LUGANO trial for DURAVYU (vorolanib intravitreal insert) in wet AMD and said the program failed to meet the prespecified primary endpoint (change in best-corrected visual acuity vs. on-label aflibercept) in the full dataset. Following the disclosure on Aug. 17, EyePoint’s stock fell by over 66%. The law firm Kessler Topaz Meltzer & Check said it is investigating potential federal securities law violations on behalf of investors who suffered significant losses.

Analysis

The market is treating this as more than a single-program miss: once a pivotal ophthalmology read fails, the equity story shifts from addressable market size to survivability, dilution, and whether the remaining pipeline has enough value to justify continued burn. For a clinical-stage name, the real damage is often delayed—over the next 1-3 months, the stock can keep leaking as investors reprice financing terms, partner leverage, and the probability of a strategic reset.

The competitive readthrough favors de-risked incumbents in wet AMD and broader retina care, not other early-stage delivery platforms. Any incremental physician or payer skepticism tends to accrue to established, reimbursed therapies with known safety/efficacy rather than to speculative alternatives, which is a modest positive for larger ophthalmology franchises and a negative for small-cap peers trying to sell convenience as differentiation.

The contrarian point is that the stock may already have discounted a large fraction of the bad news, so chasing downside after a 60%+ collapse is less attractive than waiting for the next balance-sheet signal. The key falsifier over the next 1-3 months is a credible non-dilutive partnership or a clearer cash-runway update that reduces near-term funding risk; absent that, the 6-18 month path likely remains one of lower peak valuation and repeated capital-markets overhang.

Key Decisions for Investors

• Short EYPT only on any 5-10% relief bounce over the next 2-6 weeks; the thesis is that dilution and strategy uncertainty will continue to pressure the stock. Invalidate the short on a non-dilutive partnership, a materially better follow-on dataset, or evidence that cash runway is long enough to avoid financing.
• If you want a relative-value expression, long REGN vs short EYPT for 1-3 months to capture the rotation toward de-risked retina incumbents. Risk/reward is modest but cleaner than an outright long in EYPT; the pair should work only if the market keeps penalizing speculative ophthalmology platforms.
• Add EYPT to the small-cap biotech financing watchlist and hedge XBI only if the name starts to contaminate the broader basket for several sessions. A spread move of XBI underperforming IBB by >2% would be the trigger to consider a tactical hedge.
• Do not buy the drawdown until management quantifies cash runway and the next indication path; this is a 'prove it' setup, not a mean-reversion long. Reassess only after the next earnings call or strategic update.